<SEC-DOCUMENT>0001437749-21-022018.txt : 20210913
<SEC-HEADER>0001437749-21-022018.hdr.sgml : 20210913
<ACCEPTANCE-DATETIME>20210913160927
ACCESSION NUMBER:		0001437749-21-022018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210909
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210913
DATE AS OF CHANGE:		20210913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		211249780

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dffn20210913_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dffn="http://www.dffn.com/20210909"><head>
	<title>dffn20210913_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 9/13/2021 6:00:27 PM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20218K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20218K" name="dei:EntityCentralIndexKey">0001053691</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="dffn-20210909.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20218K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-09-09</xbrli:startDate>
<xbrli:endDate>2021-09-09</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; font-variant: normal; margin: 0pt; text-align: center;"><b>FORM <ix:nonNumeric contextRef="d20218K" name="dei:DocumentType"><b><b>8-K</b></b></ix:nonNumeric></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Pursuant to Section 13 or 15(d) of</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>the Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="d20218K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b><b>September 9, 2021</b></b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 20pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityRegistrantName"><b>DIFFUSION PHARMACEUTICALS INC.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tbody><tr>
			<td style="vertical-align:top;width:33.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityFileNumber"><b>000-24477</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityTaxIdentificationNumber"><b>30-0645032</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:33.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">incorporation)</div>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number)</div>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tbody><tr>
			<td style="vertical-align:top;width:50.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressAddressLine1"><b>1317 Carlton Avenue</b></ix:nonNumeric><b>, <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressAddressLine2"><b><b>Suite 200</b></b></ix:nonNumeric></b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressCityOrTown"><b>Charlottesville</b></ix:nonNumeric><b>, <ix:nonNumeric contextRef="d20218K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince"><b>Virginia</b></ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align: bottom; width: 50.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressPostalZipCode"><b>22902</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices)</div>
			</td>
			<td style="vertical-align:top;width:50.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Zip Code)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric contextRef="d20218K" name="dei:CityAreaCode"><b><b>434</b></b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20218K" name="dei:LocalPhoneNumber"><b><b>220-0718</b></b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table cellpadding="2" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-width: thin 1px 1px; border-style: solid; border-color: rgb(0, 0, 0) black; vertical-align: top; width: 43%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Title of each class</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 25%; border-top: thin solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Trading Symbol(s)</div>
			</td>
			<td style="border-width: thin 1px 1px; border-style: solid; border-color: rgb(0, 0, 0) black; vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Name of each exchange on which registered</div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 43%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $0.001 per share</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:TradingSymbol">DFFN</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (</b>&#167;&#8201;<b>230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (</b>&#167;&#8201;<b>240.12b-2 of this chapter).</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Emerging growth company</b>&#xa0;&#xa0;&#xa0;<ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </b>&#xa0;&#xa0;&#xa0;&#9744;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Item 7.01</b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Regulation FD Disclosure</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain information concerning the business, clinical studies, development plans, and financial position of Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221; or &#8220;we&#8221;) that we expect to use at certain conferences, meetings, and presentations is available on our website, www.diffusionpharma.com, under &#8220;Investors &#8211; Presentations.&#8221; Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The information contained in the presentation is summary information that is intended to be considered in the context of the Company&#8217;s filings with the Securities and Exchange Commission (&#8220;SEC&#8221;) and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise related thereto and contained in this Current Report on Form 8-K. Such information is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of Section 18 of the Exchange Act unless we specifically incorporate it by reference in a document filed under the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as previously set forth by specific reference in such a filing.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Item 8.01 </b></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Other Events</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On September 9, 2021, the Company issued a letter to shareholders providing an update on recent events and outlook for the remainder of 2021 and early 2022. A copy of the letter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item</b>&#8239;<b>9.01 </b>&#8211;<b> Financial Statements and Exhibits</b>&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(d) Exhibits</b>&#xa0;&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit </b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Number</b>&#xa0;</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b>&#xa0;</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">&#xa0;</td>
			<td style="vertical-align: top; width: 90%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">99.1&#xa0;</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_283424.htm" style="-sec-extract:exhibit;">Letter to Shareholders, dated September 9, 2021</a>&#xa0;</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">104</td>
			<td style="vertical-align: top; width: 90%;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tbody><tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;">Dated: September 13, 2021</div>
			</td>
			<td colspan="2" style="width: 38%; width: 5%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"><b>DIFFUSION PHARMACEUTICALS INC.</b></div>
			</td>
			<td style="width: 12%; width: 10%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td style="width: 3%; width: 5%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td style="width: 35%; width: 35%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td style="width: 12%; width: 10%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td style="width: 3%; width: 5%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td align="left" style="nowrap: nowrap; width: 35%; width: 35%;" valign="bottom">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td style="width: 12%; width: 10%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>
		<tr>
			<td align="left" style="width: 50%; text-align: left; width: 50%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td style="width: 3%; text-align: left; width: 5%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </span></div>
			</td>
			<td align="left" style="nowrap: nowrap; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); width: 35%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&#xa0;</span>William Elder</div>
			</td>
			<td style="width: 12%; width: 10%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td style="width: 3%; width: 5%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;">Name:</div>
			</td>
			<td style="width: 35%; width: 35%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;">William Elder</div>
			</td>
			<td style="width: 12%; width: 10%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
			<td style="width: 3%; width: 5%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;">Title:</div>
			</td>
			<td style="width: 35%; width: 35%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;">General Counsel</div>
			</td>
			<td style="width: 12%; width: 10%;" valign="top">
			<div style="margin-top: 0; margin-bottom: 0;"></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_283424.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_283424.htm</title>

	<!-- Generated by ThunderDome Portal - 9/13/2021 6:12:58 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px">&nbsp;</p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="a01.jpg" src="a01.jpg"></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Diffusion Pharmaceuticals Issues Letter to Shareholders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">CHARLOTTESVILLE, Va., September 9, 2021 -- &nbsp;<u><b>Diffusion Pharmaceuticals Inc.</b></u><b> (NASDAQ: DFFN)</b>&nbsp;(&#8220;Diffusion&#8221; or the &#8220;Company&#8221;), an innovative biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, has issued a Letter to Shareholders. &nbsp;The letter provides an update on recent events and outlook for the remainder of 2021 and early 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The full text of the letter follows:&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Diffusion Pharmaceuticals Shareholder Letter</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">September 9, 2021</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dear Fellow Stockholders,</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I assumed the role of President and CEO at Diffusion Pharmaceuticals one year ago, in September 2020. Since that time, we have made many organizational and strategic advances and have endeavored to regularly communicate our progress. The purpose of this letter is to summarize these changes, highlight the data obtained from our clinical trials and describe how we plan to use the data to direct our development strategy for our lead product candidate, trans sodium crocetinate (TSC).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Over the coming weeks and months, we will continue to communicate our plans and progress through our usual channels, including press releases, investor conference presentations, media interviews and SEC filings. We also will seek to expand the depth and breadth of information available about our development activities through a series of podcasts featuring our Chief Medical Officer, Chris Galloway, M.D and me. The first episode of this podcast series, entitled &#8220;The Science of Solving for Hypoxia&#8221; is available through the Diffusion website at <u>www.diffusionpharma.com</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>1.</i></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Organizational Changes</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The story of every organization is primarily about its people, so let&#8217;s start there.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Since last September, there has been significant change at every level of our organization, from the Board of Directors (Board) to the management team and to our operating team. We have implemented these changes to most effectively position us for short and longer term success.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="a01.jpg" src="a01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I joined the Diffusion Board in January 2020 and was appointed CEO in September 2020. My scientific training and expertise, coupled with my significant biopharmaceutical industry experience in drug development and business development, match well with the current needs of Diffusion. Bill Hornung, our Chief Financial Officer since late 2018, is another industry veteran. Bill has been a great partner to me, both to provide historical context and in helping to shape Diffusion for the future. Last fall we further enhanced our management team with the addition of two very skilled leaders: our General Counsel, Bill Elder, and our Chief Medical Officer, Dr. Chris Galloway.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In addition to management team talent, we also have added accomplished individuals throughout the organization, including in our administration, clinical operations, finance, quality assurance, and chemistry, manufacturing and controls (CMC) functions. As we move forward, we plan to continue to grow and supplement our team as Diffusion continues to mature.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At the Board level, Jane Hollingsworth, who joined the Board in August 2020, was appointed our new Board Chair in June 2021, bringing more than 25 years of experience founding and leading life sciences companies. Diana Lanchoney, M.D., and Eric Francois &#8211; both elected to the Board in June 2021 &#8211; bring extensive technical expertise and many years of biopharmaceutical company leadership experience to the Board. Jane, Diana and Eric add meaningful new perspectives to our Board, enhancing the skills available to support the organization.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Collectively, these changes already have had a meaningful, positive impact on our ability to refine and execute our strategy, which I believe position us well for future success.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>2.</i></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Development Strategy Changes</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Let&#8217;s talk more about the changes to our development strategy over the last 12 months.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Since the founding of Diffusion, the focus has been on developing TSC as a platform therapeutic that can be used to enhance standard-of-care treatment for conditions complicated by hypoxia. Today, the development of TSC remains the cornerstone of our strategy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Over time, we have generated a substantial amount of data on TSC. This includes data on CMC, preclinical safety and efficacy data in a wide array of experimental models, clinical data on single dose safety, tolerability, and pharmacokinetics in healthy volunteers, and clinical safety and efficacy data evaluating TSC as an adjuvant therapy in the treatment of a variety of indications, as noted below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>GBM and Stroke Data</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="a01.jpg" src="a01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In late 2017, a Phase 2/3 follow-on study in GBM patients initiated, and in late 2019 a Phase 2 clinical study in acute stroke patients was initiated. However, both of these studies were terminated prior to completion due to non-clinical factors, including a lack of adequate financial resources and, in the case of the stroke study, the onset of the COVID-19 pandemic in early 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>COVID-19 Data</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In April 2020, due to the anticipated persistence of the COVID-19 pandemic coupled with the strong belief in the potential of TSC to improve low tissue oxygen levels, we announced a clinical research program evaluating TSC in patients with COVID-19. This program led to our recently completed Phase 1b clinical study evaluating TSC in COVID-19 patients.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The 24 patient, Phase 1b COVID-19 trial was completed in February 2021. This study evaluated the safety and pharmacokinetics of ascending doses of TSC administered every six hours for at least five and up to 15 days, which was a more frequent dosing regimen than had been used in previous clinical studies. Topline results from primary endpoint data, announced shortly after study completion in February 2021, indicated TSC was safe and well-tolerated when administered using the more frequent dosing regimen. Secondary and exploratory endpoint data, announced in May 2021, indicated that patients receiving the highest TSC dose tested, 1.5 mg/kg, had (i) faster time to improvement in World Health Organization ordinal scale by day 7 and through day 29, (ii) reduced time on oxygen supplementation, and (iii) reduced hospital length of stay compared to those receiving lower doses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">It is important to recall that the COVID-19 trial was designed as a safety and tolerability study only and was not designed or powered to evaluate TSC&#8217;s efficacy as a treatment for COVID-19.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Focused new development strategy</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Last fall, we took the opportunity to conduct a thorough analysis of all available data to map a strategy for future success. The available data at that point supported TSC&#8217;s potential to enhance the standard-of-care for many hypoxia-related indications but did not yet provide direct evidence of TSC&#8217;s ability to enhance oxygenation in humans nor did it yet demonstrate the safest and most effective doses to produce this oxygenation effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In order to address these outstanding questions, in November 2020 we announced our plan to conduct a trilogy of short-term, clinical studies &#8211; collectively referred to as the Oxygenation Trials &#8211; utilizing three different experimental clinical models of oxygenation:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:27pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The TCOM Trial was the first of our three Oxygenation Trials. In short, it was designed to measure the direct effects of TSC on peripheral tissue oxygenation (tcpO2) in healthy normal volunteers using a device called a transcutaneous oximeter (TCOM) that measures the release of oxygen from blood vessels through the skin. This study was completed in March 2021 and is described in more detail below.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="a01.jpg" src="a01.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:27pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Altitude Trial, which we expect to initiate in the fourth quarter of this year, is designed to measure the effects of TSC on maximal oxygen consumption and partial pressure of blood oxygen in healthy normal volunteers exercising under conditions that simulate altitude and induce hypoxia.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:27pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The ILD-DLCO Trial, which we expect to initiate in the late fourth quarter of this year, is designed to measure the effects of TSC on the diffusion of carbon monoxide through the lungs (DLCO) as a surrogate measure of oxygen transfer efficiency, or uptake, from the alveoli of the lungs, through the plasma, and onto hemoglobin within red blood cells, in patients previously diagnosed with interstitial lung disease (ILD).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;"><i>The TCOM Study</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The topline results of the TCOM study were announced in the second quarter of 2021. In this study, TSC was observed to be safe and well-tolerated at all doses tested with no serious adverse events or dose-limiting toxicities. Analysis of the primary endpoint data indicated a positive dose-response trend in TCOM readings with TSC as compared to placebo that persisted through the measurement period. Due in part to the small number of subjects in each cohort, and the inherent variability of tcpO2 measurement, the magnitude of effect was not statistically significant; however, the trends in the primary endpoint data indicated an improvement in peripheral oxygenation with TSC with no evidence of hyperoxygenation, a potentially toxic condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The figure below was created by subtracting the median response observed in the TCOM Trial&#8217;s placebo group from the median response observed in each TSC dosage group at each of the measurement times during the one-hour period following dosing. As you can see, these data show increasing peripheral tissue oxygenation following TSC administration that persisted through the one-hour measurement period, particularly at the two highest doses tested (2.0 mg/kg and 2.5 mg/kg).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="ex_283424img001.jpg" src="ex_283424img001.jpg" style="width:550;height:395;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-align: center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 25%;">&nbsp;</td>
			<td style="width: 50%;">Figure 1. Effects of TSC on transcutaneous oxygen pressure (tcpO2). The graph&nbsp;was created by subtracting the median placebo response from the dose and&nbsp;time matched median TSC response.</td>
			<td style="width: 25%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="a01.jpg" src="a01.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We believe the TCOM Trial provides clinical evidence of exactly the outcomes we were hoping to see - that TSC facilitates the passive diffusion of oxygen from areas of high concentration to areas of low concentration without causing hyperoxygenation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">While the results of the TCOM study were not statistically significant - due we believe to the small sample size and the innovative trial design - they represent a positive and meaningful step towards the accomplishment of the strategic objectives of our Oxygenation Trials. Moreover, the 2.0 mg/kg and 2.5 mg/kg doses at which the effects of TSC were observed in the TCOM study are higher than the doses tested in any of the recent clinical trials of TSC. Therefore, in addition to providing evidence of a direct effect of TSC on oxygenation, these results help inform dose selection for future trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>3.</i></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Looking Ahead</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The body of data we have amassed to date makes us optimistic about the broad therapeutic potential of TSC. We believe the two remaining Oxygenation Trials &#8211; our Altitude and ILD-DLCO Trials &#8211; will answer additional outstanding questions, providing important additional data related to TSC dose and oxygenation as well as the mechanism of action. This information will guide our selection of the initial TSC indication to be studied for regulatory approval, which we expect to announce in the fourth quarter of this year.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Perhaps equally important to the progress we have made in our clinical program, as of June 30, 2021, we believe we have sufficient cash resources to fund our planned clinical trials and other operational needs through 2023. This includes the capacity to fully fund a Phase 2b clinical study evaluating TSC in the initial indication we will choose and identify in the fourth quarter of 2021 and expect to commence in the first half of 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Looking forward, our team is committed to maximum effort, good planning, and strong execution as we strive to realize the potential of TSC for patients and for you, our stockholders. We are excited about Diffusion&#8217;s prospects for the future and remain focused on executing the plan we have designed to develop TSC. We will continue to endeavor to win your confidence, successfully demonstrate the clinical value of TSC, and build a foundation for the future growth of Diffusion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On behalf of the entire Diffusion team, I thank you for your continued support.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Best wishes for your health and safety,</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Robert J. Cobuzzi Jr., Ph.D.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">President and CEO</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Diffusion Pharmaceuticals Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most. Diffusion&#8217;s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion&#8217;s product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development. For more information, please visit us at <u>www.diffusionpharma.com</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="a01.jpg" src="a01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company&#8217;s near-term strategic priorities and the potential therapeutic value of TSC. The Company may, in some cases, use terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control, and as a result, the Company&#8217;s actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risk and uncertainties include, among other things, those related to: the Company&#8217;s ability to design, initiate, enroll, execute, and complete its ongoing and planned studies evaluating TSC; the optimal doses and dosing regimens of TSC in connection with the potential treatment of any particular disease or indication; general economic, political, business, industry, and market conditions, including the ongoing COVID-19 pandemic; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s filings most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule, or regulation, the Company undertakes no obligation to update any such statements after the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contacts</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investors:</b>&nbsp;&nbsp;<br>
<u>Tiberend Strategic Advisors, Inc.</u>&nbsp;<br>
Maureen McEnroe, CFA / Lisa Sher&nbsp;<br>
<u>mmcenroe@tiberend.com</u>&nbsp;/&nbsp;<u>lsher@tiberend.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Media:</b>&nbsp;&nbsp;<br>
Kate Barrette<br>
RooneyPartners<br>
(212) 223-0561<br>
<u>Kbarrette@rooneypartners.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dffn-20210909.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/13/2021 6:10:00 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dffn="http://www.dffn.com/20210909" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.dffn.com/20210909">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20210909_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20210909_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20210909_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.dffn.com/20210909/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="dffn_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>dffn-20210909_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/13/2021 6:10:00 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.dffn.com/20210909/role/statement-document-and-entity-information" xlink:href="dffn-20210909.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.dffn.com/20210909/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>dffn-20210909_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/13/2021 6:10:00 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line Two</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>dffn-20210909_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 9/13/2021 6:10:00 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.dffn.com/20210909/role/statement-document-and-entity-information" xlink:href="dffn-20210909.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.dffn.com/20210909/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>a01.jpg
<TEXT>
begin 644 a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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M<\5)X.^&_P 1/#T&HRZY<SI"-$(ECD4REB$S%<1JCJ2 2K+D9S0*QWO[(O\
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M#0KD?CG\=_"'[-/POU3QIXZUZQ\-^&='0/=WUVQV1[F"JH !9F9B %4%B3@
MUXK:_P#!9']EN]\2?V5'\<O /VK?Y>Y[_9;YZ?ZX@18]]V*H_P#!6;X&_#7]
ML/\ 8(U;1?''Q'TGP#X3OYK/4;#Q7+=1?88)PP-NY9G5)(Y-^W <;@X(.<4
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M5MK'!(.#V- 'YHWVD_%#]A+X*_L<_%JS^.'Q#\42^.O$7@_P5XG\)ZC);_\
M",3Z=JENL06TLTB!MI+?Y"DN]G?:=[-DU;_X*>_M#ZQK.J?';Q-\$_&'[4>L
M>+/@O9327UYX9U33K+P'X0O[.S6=[6XANC$+X@ //&HN'7S"H*G"C[M^+/[!
MO@?XS_!WX8^!]8DUQ=%^$NMZ)K^AFWNU29KG20!:^<Q0AT.!O "[NQ%>6?%#
M_@B_\,_BCXG^)LLGBKXJ:'X5^,5Q/J'B_P (:-XC-GH>LWTT0BENVC$9E61P
M%9E641NR+O1AE2 > ^/OBE\6/VVOVT/V;?!FD_%;Q9\*_"WQ6^!C>-O%:>%Y
M4ANFD\VRDQ:22(X@E+SJGF[2PBWA<%@1K^'?AI\2_P!LW_@HM^U7\,YOC]\6
MO O@CX6Q>%ET*W\,ZC%:WB7EYHP=II+AHV<Q!XFD:%=JR/*Q8D "OK3X<_L
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M\+;N;Q1_PC/QO\77'C3Q$R7Z"Z6_FN+:X<0/Y9$<>^TBPI5B!NYYR/1_C?\
MLD^%?C_\0/A;XDUV35DU'X0ZXWB#0Q:W"QQO<M;2VQ$P*DNGERMP"IS@YQP0
M#X\_8X\'>.O^"JEIXV^+?BCXX?%CP%I=EXWU?P]X7\)>!M8BTBTT2TTV[>U4
MWO[EWNKF5HS(XE)0*ZA4 K]$8T\N-5RS;1C)ZFOE;Q%_P21\&I\8_$_C+P/\
M0OC%\))/'.H?VMXETGP7XE%AI6M7IQONF@DBD$4TF!O> QEL9//->P_!G]E_
M2?@E\6/B1XPT_7/%VJ7WQ.U&WU*_M-5U5[NRTUX8?*5+.(C$"$<LHSDXZ
M ]*HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex_283424img001.jpg
<TEXT>
begin 644 ex_283424img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &+ B8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH BFN(+95:>:.(,VU2[!<GT&>].$T1F,(D3S0NXIN&X#UQZ5G:O
M'OEMFBDG6Z1LQ!$+(W(R'X(QQU.".U4(X9?^$@15A=95O7GEE\LA6A,)51OQ
M@_,4XSGY?:@#HZ**X?PGX;M-3\&Z'?WE]KDEU=:?!-,_]N7@W.T:EC@2X&23
MTH [BBN?_P"$-TO_ )^M<_\ !]>__'J/^$-TO_GZUS_P?7O_ ,>H Z"BN?\
M^$-TO_GZUS_P?7O_ ,>H_P"$-TO_ )^M<_\ !]>__'J .@HKG_\ A#=+_P"?
MK7/_  ?7O_QZC_A#=+_Y^M<_\'U[_P#'J .@HKG_ /A#=+_Y^M<_\'U[_P#'
MJ/\ A#=+_P"?K7/_  ?7O_QZ@#H**Y__ (0W2_\ GZUS_P 'U[_\>H_X0W2_
M^?K7/_!]>_\ QZ@#H**Y_P#X0W2_^?K7/_!]>_\ QZC_ (0W2_\ GZUS_P '
MU[_\>H Z"BN?_P"$-TO_ )^M<_\ !]>__'J/^$-TO_GZUS_P?7O_ ,>H Z"B
MN?\ ^$-TO_GZUS_P?7O_ ,>H_P"$-TO_ )^M<_\ !]>__'J .@HKG_\ A#=+
M_P"?K7/_  ?7O_QZC_A#=+_Y^M<_\'U[_P#'J .@HKG_ /A#=+_Y^M<_\'U[
M_P#'J/\ A#=+_P"?K7/_  ?7O_QZ@#H**Y__ (0W2_\ GZUS_P 'U[_\>H_X
M0W2_^?K7/_!]>_\ QZ@#H**Y_P#X0W2_^?K7/_!]>_\ QZC_ (0W2_\ GZUS
M_P 'U[_\>H Z"BN?_P"$-TO_ )^M<_\ !]>__'J/^$-TO_GZUS_P?7O_ ,>H
M Z"BN?\ ^$-TO_GZUS_P?7O_ ,>H_P"$-TO_ )^M<_\ !]>__'J .@HKG_\
MA#=+_P"?K7/_  ?7O_QZC_A#=+_Y^M<_\'U[_P#'J .@HKG_ /A#=+_Y^M<_
M\'U[_P#'J/\ A#=+_P"?K7/_  ?7O_QZ@#H**Y__ (0W2_\ GZUS_P 'U[_\
M>H_X0W2_^?K7/_!]>_\ QZ@#H**Y_P#X0W2_^?K7/_!]>_\ QZC_ (0W2_\
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M?7O_ ,>H Z"BN?\ ^$-TO_GZUS_P?7O_ ,>H_P"$-TO_ )^M<_\ !]>__'J
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M@@**S];U7^Q-'GU#[!?7_D[?]&L(?-F?+!?E7(SC.3[ US]IX^^UZ/J.H?\
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M],=-.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5WB.4)[=./<<#@\<#TJS10!6>QMY)A+(K,P;> 9&*YXP=N<<8&..#S5FBB@
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M\R<YVX'(!S0 ZTU1+W2_M\%O*\;9,2HT;&4=BI5BN#[D8[XJ>RNTOK1+A$=
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M .&^\UDJ?(G%Z]3UNBN/\(_$WPMXTVQ:;?>5?-G_ $&[ CF_BZ#)#\*6^4G
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MZX^;VK5GL;>YFCEF0NT9RH+';G.02,X.",\BD6PM4O6O%A47#C#/Z]!G'3.
M!GK@"@"S7/\ @3_DGGAG_L%6O_HI:Z"N?\"?\D\\,_\ 8*M?_12T =!1110
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M3_DGGAG_ +!5K_Z*6N@KG_ G_)//#/\ V"K7_P!%+0!T%%%% !1110 4444
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M^SM;WC@O^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\ Y)7'_P ;KT"BNLR//_\
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M4O*T4@AD1!M^3)\M1GG!VM@YSQ@5ZQ13$>3S?&FXT/[0?%O@77-(C240QRQ
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MJ-YI5C<7T&WR;F:W1Y(]IW+M8C(P22,=#0!PFF?#GQ9HVMF^M?B5JEQ;;_\
MCTOX3<!HMP.PL[D!B!C>J@]< 9Q4OB3P7-XNTQH-:U+5K73K9F>XBM7=GN%
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M4M=!7+^"[VVMO GA2":94DFTNU$:GO\ ND_+D@<]R!WH ZBBJS:A:)J"6+3
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M(G49(N5A&%5W+ $D$'RD=0H*UZ+14\KYN:_R-W5@Z*I<BO>_-K?T[!1115&
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M.  4[;<]ZZ# ].M 4#. !DY.!UH 6BBB@ HHHH **** "BBB@ HHHH ****
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M;)::;#%'$(EP7\L# 3<2Q'X$XIMQK&GVET+:>Z5)3C@@\9Z9/0?C7.ZG\5/
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M<+'AU!5BI0\G>&8@;5+'TCPQX8TOPCH<.D:1!Y5O'RS-R\KGJ[GNQQ^@
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MA%' S@$\D=,#D@'<KA_"NIV7Q"O$\3R:-Y4.DW=Q!H]Z9Y,SHPV/*$*J K#
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M8Z1;-!86L,"N_F2&.-5,KD %VP!EC@9)Y-7** "BBB@ KR#5?!]S<:3K]O\
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MQ!*(GVDYBMP?F9MIW*IZ$[2"BR^E>@:'HUGX>T.RTBP39:VD2Q)D %L=6;
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M[LG=G=ELY.Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/\
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M;Z7I]I8P,^]H[6%8E+8 R0H S@#GV%7* "BBB@ HHHH **** "BBB@ HHHH
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M@R3W(YP!DD [%8_V?7?^$R^T_;8/^$>_L_R_LFT>9]J\S._.W[NSC[W7MWH
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M< #K0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MY_P)_P D\\,_]@JU_P#12UT%<_X$_P"2>>&?^P5:_P#HI: .@HHHH **** "
MBN=UR\GG@MX(BUI'),RRO<.80X5"0H8<@$@<CL#532;QKF]L9T$D5Q-,1+;/
M(28H/(W*"N>,-Y?..K'U- '6US_@3_DGGAG_ +!5K_Z*6N@K,TO1ETC2++3+
M:]NC;V<"6\1?RRVU%"C)V]<"@#3HJO\ 9Y?^?V?_ +Y3_P")H^SR_P#/[/\
M]\I_\30!8HJO]GE_Y_9_^^4_^)H^SR_\_L__ 'RG_P 30!8HJO\ 9Y?^?V?_
M +Y3_P")H^SR_P#/[/\ ]\I_\30!8HJO]GE_Y_9_^^4_^)H^SR_\_L__ 'RG
M_P 30!8HJO\ 9Y?^?V?_ +Y3_P")H^SR_P#/[/\ ]\I_\30!8HJO]GE_Y_9_
M^^4_^)H^SR_\_L__ 'RG_P 30!8HJO\ 9Y?^?V?_ +Y3_P")H^SR_P#/[/\
M]\I_\30!8HJO]GE_Y_9_^^4_^)H^SR_\_L__ 'RG_P 30!8HJO\ 9Y?^?V?_
M +Y3_P")H^SR_P#/[/\ ]\I_\30!8HJO]GE_Y_9_^^4_^)H^SR_\_L__ 'RG
M_P 30!8HJO\ 9Y?^?V?_ +Y3_P")H^SR_P#/[/\ ]\I_\30!8HJO]GE_Y_9_
M^^4_^)H^SR_\_L__ 'RG_P 30!8HJO\ 9Y?^?V?_ +Y3_P")H^SR_P#/[/\
M]\I_\30!8HJO]GE_Y_9_^^4_^)H^SR_\_L__ 'RG_P 30!8HJO\ 9Y?^?V?_
M +Y3_P")H^SR_P#/[/\ ]\I_\30!8HJO]GE_Y_9_^^4_^)H^SR_\_L__ 'RG
M_P 30!8HJO\ 9Y?^?V?_ +Y3_P")H^SR_P#/[/\ ]\I_\30!8HJO]GE_Y_9_
M^^4_^)H^SR_\_L__ 'RG_P 30!8HJO\ 9Y?^?V?_ +Y3_P")H^SR_P#/[/\
M]\I_\30!8HJO]GE_Y_9_^^4_^)H^SR_\_L__ 'RG_P 30!8HJO\ 9Y?^?V?_
M +Y3_P")H^SR_P#/[/\ ]\I_\30!8HJO]GE_Y_9_^^4_^)H^SR_\_L__ 'RG
M_P 30!8HJO\ 9Y?^?V?_ +Y3_P")H^SR_P#/[/\ ]\I_\30!8HJO]GE_Y_9_
M^^4_^)H^SR_\_L__ 'RG_P 30!8HJO\ 9Y?^?V?_ +Y3_P")H^SR_P#/[/\
M]\I_\30!8HJO]GE_Y_9_^^4_^)H^SR_\_L__ 'RG_P 30!8HJO\ 9Y?^?V?_
M +Y3_P")H^SR_P#/[/\ ]\I_\30!8HJO]GE_Y_9_^^4_^)H^SR_\_L__ 'RG
M_P 30!8HJO\ 9Y?^?V?_ +Y3_P")H^SR_P#/[/\ ]\I_\30!8HJO]GE_Y_9_
M^^4_^)H^SR_\_L__ 'RG_P 30!8KG_ G_)//#/\ V"K7_P!%+6Q]GE_Y_9_^
M^4_^)I-.L+?2],M=/M$*6UK"D$2DDD(H"@9/7@"@"S1110 4444 ->-)4VR(
MKJ>S#(HV)O+[5WD8+8YQZ4ZB@!LDD<,;22NJ1J,LS'  ]2:565T5T8,K#(8'
M((K*\0(6L8':)I88KF*69%0N2BMG.T<G!P?PI?#L4L6C()59-TT\D:,I4K$T
MKM&I!Y&$*C';&* -6BBB@ J*XN(+6%IKB:.&)?O/(P51VZFI:R?$$4<VGA6F
MNX90VZ%[:,NP?! ^7!!'/1AB@#55E=0RL&5AD$'((I:9#YGD1^<%$FT;PO0'
M'.*?0 4444 0+>6KVS7*7,+6ZYS*'!48Z\].*F5E=%=&#*PR&!R"*Y"(B71Y
MF^SS-#!K#RS1FW?)3SBVX*1EAR&XSTK;\.Q2Q:,@E5DW33R1HRE2L32NT:D'
MD80J,=L8H U:*** (YIX;:%IIY4BB7EGD8*H^I--GN[:U1'N+B*)78*C2.%#
M$] ,]35+Q%_R+6J#8SEK650J(6))4@  <FJ-\%N;;3)K>6[2[55:!5A;:P)7
M<) 5P!@<DX([8- '0T444 %12W,$$D:2SQQO*=L:NX!<^@]34M87B)K%XX[:
MZB=GE96#I;/*5".&X*J<'(XSCGGM0!LB>$SF 2H9@NXQ[AN ]<=<5)7*Q6\W
M_"3QJL$BS)J$ES/-Y1"O;F HHWXP?F,8VYS\A]*ZJ@ HHHH B:Y@6Y6W:>,3
MN"RQ%QN8#N!UQ2)=6\ES);)<1-/& 7B5P67/3(ZBLC4VL9=:L8)(G^T13+,)
M$MG;G#*!O"X'4YR>GUJ32XO+U>]:WEN7MG^9UGC("2[CG82 2#GD<@8&,9-
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MS-87%K8O':E=DAD_=.5 _=941N<X VGIBN]H **** &2S101F2:1(XQU9V
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# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>dffn20210913_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dffn-20210909.xsd" xlink:type="simple"/>
    <context id="d20218K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2021-09-09</startDate>
            <endDate>2021-09-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20218K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20218K">0001053691</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20218K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20218K">2021-09-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20218K">DIFFUSION PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20218K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20218K">000-24477</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20218K">30-0645032</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20218K">1317 Carlton Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="d20218K">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="d20218K">Charlottesville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20218K">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20218K">22902</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20218K">434</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20218K">220-0718</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20218K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20218K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20218K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20218K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20218K">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20218K">DFFN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20218K">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20218K">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139941052262296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">DIFFUSION PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Sep.  09,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">000-24477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">30-0645032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">1317 Carlton Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity, Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Charlottesville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">22902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">220-0718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DFFN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "V!+5,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  M@2U3CBRC8>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$G8H";UI66G#08K;.QF;+4UC6-C:R1]^R5>FS*V!]C1TN]/
MGT"M#D+[B"_1!XQD,=V-KNN3T&'-CD1! "1]1*=2.27ZJ;GWT2F:GO$ 0>F3
M.B#4G#^ 0U)&D8(96(2%R&1KM- 1%?EXP1N]X,-G[#+,:, .'?:4H"HK8'*>
M&,YCU\(-,,,(HTO?!30+,5?_Q.8.L$MR3'9)#<-0#DW.33M4\/[\])K7+6R?
M2/4:IU_)"CH'7+/KY+=FL]T],EGSNBKXJJB:7<T%7XGZ_F-V_>%W$W;>V+W]
MQ\970=G"K[N07U!+ P04    "  M@2U3F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M "V!+5.DM[-F4P0  /T0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9C1;N(X%(:O9Y_"XFI7:DMBH)0114JA[$334K:A,]*N]L(D!JPF=L9Q2GG[
M/0XT8;7AA-'>D#BQ?W\^/O[M,-PJ_9IM.#?D/8EE=MO:&)-^;K>S<,,3EEVI
ME$MXLU(Z80:*>MW.4LU95#1*XC9UG.MVPH1LC8;%L[D>#55N8B'Y7),L3Q*F
M=W<\5MO;EMOZ>/ LUAMC'[1'PY2M><#-2SK74&J7*I%(N,R$DD3SU6W+<S_?
MT9YM4-3X)O@V.[HG=BA+I5YMP8]N6XXEXC$/C95@<'GC8Q['5@DX?AQ$6V6?
MMN'Q_8?ZM!@\#&;),CY6\7<1F<UMZZ9%(KYB>6R>U?8+/PRH  Q5G!6_9+NO
MV^VU2)AG1B6'QD"0"+F_LO=#((X:=-P3#>BA 2VX]QT5E!-FV&BHU99H6QO4
M[$TQU*(UP EI9R4P&MX*:&=&$Q7F$&1#/!F1>VF$V1%?[F<;HC9L&^C$5FV'
M!\&[O2 ](1CP](HX@PM"'>K^NWD;V$I 6@+20J_3!'A$1?YZ@%K$-SS)_D;Z
MZ)1]=(H^NB?ZV(_[@CSSM<B,9M#;C"6\;O"XT,2?3E\"_VE&YE^\YT=O?/^R
M\,?>0T#\V?@*(>V6I%V\@T,T+LABE]8"XNUO+K\B%+V2HG<FQ9QKH6SB1 32
MKQ8(ERK297#QRZ=/#?ER7;)=GS67O@R53I4N$N:"! ;PB-)DK')I] ZN42TN
MKCZY1Q#[)6+_+,2IB#F9Y<F2ZSH27,1QG$O:[?;["-!-"71S%M""O1,_@HD5
M*Q'N5]II/%RRXUPZU]V>TZ$(WZ#D&YS%YT61YEE6WI#"!IYD[43BDF['[9,Q
MT[&!07IO7.8< 76=RDZ=_X&ZV*I:1\4U@UQ [L(^BQ$>&;[[<X1CZ_FP,A9J
M6^_WN-YX U%4QO#L3<0Q&L7*\UWZ<XSE\IUK]29D6#OC#:+?/(RMVBO<\S:+
MDFVN,L-B\J=(3YI*@R2E P=;)VZU/;BXOQ=SZ<'Q[#0*+M#M=#&0:H=P<5]_
M4"'$9+Y1$K.X!A%*P47Z[@U&5.T++F[=W[6 ))40F"3)Y<'?LEHJ7&C%X@Q-
M\VH?<'$/#U0L0F&$7)-'R&\M6%S+@ZLT\E3;@(N;]ESSRQ#"PV&!%6>N!9<1
MU^1IM3HQ?[A>(UFU ;BX7?^'S,^R',@: 7'9)D!:^3[%/7HA#&SF:D5<^NOR
M-Q+P,(=\V]4Q-2C9_(0]*3 J?,70*L.GN$$O-(MLB@6[9*EJ$ZQ!8#*=SC"2
MHZ,\[L ?42'W[^&&R34_><QN$)IYP<3[ V.J[)R>9^?W"==K&Z;?0<)LK$VD
M3-9/(*[8F%25FU/<C#U(]:A(]VG,UK4HN$ C2N7G%+?BCS"-@4:#L_NP[M[)
M5UX?(%P+CJZNT^M<#VK/^^VCCUG[Q\ CL_.2D9BO0,VYZH.XWG]K[PM&I<7W
M[1(.(2HI;C><@2W8"O!^I93Y*-A/YO(?C]$_4$L#!!0    ( "V!+5.?H!OP
ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "V!+5,D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( "V!+5-ED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dffn20210913_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dffn.com/20210909/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="dffn20210913_8k.htm">dffn20210913_8k.htm</File>
    <File>dffn-20210909.xsd</File>
    <File>dffn-20210909_def.xml</File>
    <File>dffn-20210909_lab.xml</File>
    <File>dffn-20210909_pre.xml</File>
    <File>ex_283424.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dffn20210913_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "dffn-20210909_def.xml"
     ]
    },
    "inline": {
     "local": [
      "dffn20210913_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dffn-20210909_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dffn-20210909_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dffn-20210909.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 27,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "dffn",
   "nsuri": "http://www.dffn.com/20210909",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20210913_8k.htm",
      "contextRef": "d20218K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.dffn.com/20210909/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20210913_8k.htm",
      "contextRef": "d20218K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity, Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dffn.com/20210909/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001437749-21-022018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-21-022018-xbrl.zip
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M[>&WI^%Q)C 5?H03?XOQ$2&2<!YASB'6$MVE3_5_HWK^[>!.L5[(:9#B9$'
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MA9?)1<$?82:7T#DQF3H2\G5="!?ZJJ.EP# KK,@3VBW#@8$.W>J*/&RFL$V
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MD:%H$1JK<!_0XO'+9":/R\BG,"CH3E9J_\>' SYK(41,)%^XY[' ?H%>)T;
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M;71G%'0RK@8%4Z2K(%02&3$70S"/0#C.E22@Q4%.Q<<7EP9%1SZS'/NI!.&
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M%:_FN@D%MYX@O,9&MWI@*W/5N)BWM%>QW7R)O0K0I8I-R4[5J=]>S/N2NP8
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M4C_N2T-B3(=V.UVE%?E+I)U*4MN%X*SPZV<.(W0!5"77&2:"!YD+1@TQ4Z)
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M#$$6:N\IHY4L. =B>0YK)W "9 -^S^S<B%8 _"B!,FN((4Z( II$4Q$C7T$
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MQX3ZVJ=;R+9O4< H[$UV.8CZU;!:*G@X4J_8H[C@<(=GIZI;JB2<A-A&"KU
MJ&2)VJ)U/W/)<9*]*J5\MG#F_I*T'Z;AGK3!-6F?6L^O7QCTJ:]L^I6[];9N
M[9_/#H_&NN"66P7OT%)(C>D[>QWA]!K=>M.M2ZRL+$K3<<A9!CLN-+>10-8/
M0X+,/C,$R.3:<7ZNH7Q1N"4;%SZW,O(7]O )ZE":SC>=>^0(8:38%J8;/Q\+
MLP7'J>1V(%Q-96$@MUDS:=R$SVX.DCTY.V<(*/%4K[4ZQD11)Z<_39[B-+"6
M)<,\,H>SQ^2:OGOUY,?'1Q?-X_S\[7OU3C?I4L-TY?MMG23GA2HE$W(=%Z/B
M>E-UBN-X.!PQ\.C(GY3S&9>VIM5LZ[MUV\]]G.L^SG7'XESW-:O^/TKW5-S'
M27 GSQ"G@GCZU0N5/PJ(R/59!G?1]5@$^?O\!<,$T!0"7/'@,S_XNAM\2!3V
M.5>%+\>*/]^13PO1?D8N8R6WQ[VF'PM1/.\-AP:.))ZP^^S94P9I= [7,!G6
MNZK,0E=)\#D'=Q2S*BE(ZD_D<J N>,/%M:3'$$,:G-T>8)Y#_U$R-GSSQ$4K
MCH[4N+L^ELOZ^/9%ZJF&=YIBM/[R.0\BU5&X8\Y_#N@R1SAR_8N^_L_F.PRW
M;'S,-PZN?X@TZR+9^!AC7_LH=FV6;#P'>;K^(5SU]<_J]+K7&;Z\X@EF?8>X
M<9(1L*636)L8")=FI0!G5KC^4O)%O3_>9]EVD5XDZ > 2J)*-S/@%%!SVN7-
MA?4+2R(#L W7 @8^K&M72 A((VT7CA_G#=[8 SO#<F<G3#^+B[-NW@XS'K&M
M5,&W,N""1Y>1L5K9VM\SV5.!+S+TEAI_P;]'G4$FJ+#F[,N5\XR\SO_^Y@E!
M/_P<$8&+KGT:EU9(:2<.TC%;^#/A2"<RE>2V^JPCH(5>'$AECR /?+CQ1CI,
MR4@+*8H\]<V9!X$3H9POA$8CT4WKCRE(P9: YN]?/YNAN0[T*>H.=N!" 2(+
MT<67N/>%=?UQ6KY1CKIUX=J&@.B&H_=C</7 5Z=H^ B5C^?"&![5[^G"N9;/
M5Q4^0M#5[!K(H%%!7J)DG]'9G91PU0##/?#%D#.%K'B7VQB%_FGR\'NB[@*@
MJ+M^)_)W/%079FB@#^6JI)D*"38JCAUTDE,6QM<AQ.CBEME!#GIQ/2%_Y867
M"^^QWJ?R?'?I9G'M OHK3,73\%'KHZ( B[XW?-D#T>\4>F)W9_+C %X/+W:T
M_<?T;#K4-'P+Q96_#.\8*&TMMQP=W<:W/L5\0SG6I=$7ONA-E_; ?@M$ OW]
M$%?602G ![&H+<2'W6KH$42 O#BCO?-("C.:J]B4#9Y +2A;258@B51X9A!/
MF5Y&JFIQXV$?->KJFP<QQXO0<*2O<,K-LJ!><5FPW$F/QWAH@UE*T:NU2?P1
MT8YU*^L8LCK^*#;5>E>O_-6]]3XZD]GY.<XJLO;;PW,[,WRJXZRS3(X2<C>Y
MGJ> +.WAX)4WFC0&>?)OXI<DNVCACT^/U&,RFFJMSFB-QJWG>0P19_[>^&Z"
MFRJ//?9/MX=93>]N/+4%BXWKM/3UU/\1;/U"5Q7NZ>9/WCO<MO-.;AVK^:.'
M>[M[C]3>WI/)SM.O=@-=?YSYU_Y>\2O^HK+Z,Q!NX&B^/CH[G_1N\[5N_>_J
MK@=?D'X!1$;33IL\._Q?4$L! A0#%     @ +8$M4R6LGOYN P  )PX  !$
M             ( !     &1F9FXM,C R,3 Y,#DN>'-D4$L! A0#%     @
M+8$M4SM51G3G!   9BX  !4              ( !G0,  &1F9FXM,C R,3 Y
M,#E?9&5F+GAM;%!+ 0(4 Q0    ( "V!+5.O*04+#P8  &L^   5
M      "  ;<(  !D9F9N+3(P,C$P.3 Y7VQA8BYX;6Q02P$"% ,4    "  M
M@2U3#U\]%X $   U+P  %0              @ 'Y#@  9&9F;BTR,#(Q,#DP
M.5]P<F4N>&UL4$L! A0#%     @ +8$M4W_]91J\$@  R7L  !,
M     ( !K!,  &1F9FXR,#(Q,#DQ,U\X:RYH=&U02P$"% ,4    "  M@2U3
M[H0&6?@<   3B@  #0              @ &9)@  97A?,C@S-#(T+FAT;5!+
4!08     !@ & (0!  "\0P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
